Fulvestrant NON NICE approved indications | Search results | NICE

Showing 1 result for fulvestrant non nice approved indications

Sort by

Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (TA421)
Evidence-based recommendations on everolimus (Afinitor) for treating advanced breast cancer in adults after endocrine therapy.
Result type
Technology appraisal guidance
Published
21 December 2016
View recommendations for TA421
Show all sections
Sections for TA421